SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 4, 2020
Kiniksa Pharmaceuticals, Ltd.
(Exact name of Registrant as Specified in Its Charter)
|(State or other jurisdiction of
incorporation or organization)
Kiniksa Pharmaceuticals, Ltd.
2 Church Street
Hamilton HM11, Bermuda
(Address, zip code and telephone number, including area code of principal executive offices)
Kiniksa Pharmaceuticals Corp.
100 Hayden Avenue
Lexington, MA, 02421
(Address, zip code and telephone number, including area code of agent for service)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading
|Name of each exchange on which|
|Class A Common Shares $0.000273235 par
|KNSA||The Nasdaq Global Select Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 4, 2020, Kiniksa Pharmaceuticals, Ltd. (“Kiniksa”) and its Executive Vice President, Chief Financial Officer, Chris Heberlig, agreed that he will transition to a consulting role with the company on March 20, 2020. In connection with the transition, Kiniksa plans to enter into a consulting agreement with Mr. Heberlig, the terms of which have yet to be determined. As Kiniksa prepares for the potential commercial launch of its lead program, rilonacept (KPL-914), the company has commenced a search to appoint a new Chief Financial Officer to assist the company in its next phase of growth.
On February 4, 2020, Michael Megna was appointed to the role of Chief Accounting Officer in addition to his current role as the company’s Vice President, Finance, and assumed the role of principal accounting officer from Mr. Heberlig. Upon Mr. Heberlig's transition to a consulting role, Mr. Megna will assume the role of principal financial officer from Mr. Heberlig. As the company’s Vice President, Finance (since July 2018), Mr. Megna, 49, oversees the company’s accounting and finance functions. From July 2012 until July 2018, Mr. Megna served in roles of increasing seniority at LFB USA, Inc./rEVO Biologics, Inc., a biopharmaceutical company, most recently as Senior Vice President, Finance & Accounting. In those roles, Mr. Megna oversaw finance, IT, human resources and project management functions. Mr. Megna received his bachelor’s of business administration from Siena College. Mr. Megna is also a Certified Public Accountant.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|KINIKSA PHARMACEUTICALS, LTD.|
|Date: February 5, 2020||By:||/s/ Thomas Beetham|
|Chief Legal Officer|